Darovasertib is under clinical development by Ideaya Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Darovasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Darovasertib overview

Darovasertib (IDE-196) is under development for the treatment of metastatic uveal melanoma, uveal melanoma (adjuvant therapy), non-small cell lung cancer, colorectal cancer, pancreatic cancer, hepatocellular carcinoma, and cutaneous melanoma. It is administered through the oral route as a tablet formulation.  The drug acts by targeting GNAQ/11 mutated protein kinase C. It was also under development for Sturge-Weber syndrome.

Ideaya Biosciences overview

Ideaya Biosciences (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK, and other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.

For a complete picture of Darovasertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.